EUVIMEDEUVIMED entdecken
Open Access

Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex

Naoto Kuyama iD, Satoshi Araki iD, Koichi Kaikita iD, Nobuhiro Nakanishi, Naoya Nakashima iD, Shinsuke Hanatani iD, Yuichiro Arima iD, Masahiro Yamamoto iD, Taishi Nakamura iD, Eiichiro Yamamoto, Kenichi Matsushita iD, Kunihiko Matsui iD und 1 weitere

Journal of the American Heart Association · 17.09.2024 · 13 (18)

DOI: 10.1161/jaha.123.030941 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 17.09.2024. Verfasst von Naoto Kuyama und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine Graduate School of Medical Sciences, Kumamoto University Kumamoto Japan. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Receptors, Mineralocorticoid, Mice, Inbred C57BL, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mineralocorticoid receptor (MR) induces cardiac inflammation cooperatively with nuclear factor‐κB and signal transducer and activator of transcription 3 (STAT3); MR blockers exert anti‐inflammatory effects. However, the underlying mechanism remains unclear. We investigated the anti‐inflammatory effect of esaxerenone, a novel MR blocker, in experimental myocardial infarction (MI) and its underlying mechanisms. Methods and Results Male C57BL/6J mice subjected to ligation of the left anterior descending artery were randomly assigned to either the vehicle or esaxerenone group. Esaxerenone was provided with a regular chow diet. The mice were euthanized at either 4 or 15 days after MI. Cardiac function, fibrosis, and inflammation were evaluated. Esaxerenone significantly improved cardiac function and attenuated cardiac fibrosis at 15 days after MI independently of its antihypertensive effect. Inflammatory cell infiltration, inflammatory‐related gene expression, and elevated serum interleukin‐6 levels at 4 days after MI were significantly attenuated by esaxerenone. In vitro experiments using mouse macrophage‐like cell line RAW264.7 cells demonstrated that esaxerenone‐ and spironolactone‐attenuated lipopolysaccharide‐induced interleukin‐6 expression without altering the posttranslational modification and nuclear translocation of p65 and STAT3. Immunoprecipitation assays revealed that MR interacted with both p65 and STAT3 and enhanced the p65–STAT3 interaction, leading to a subsequent increase in interleukin‐6 promoter activity, which was reversed by esaxerenone.

Conclusions

Esaxerenone ameliorated postinfarct remodeling in experimental MI through its anti‐inflammatory properties exerted by modulating the transcriptional activity of the MR–p65–STAT3 complex. These results suggest that the MR–p65–STAT3 complex can be a novel therapeutic target for treating MI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorReceptors, MineralocorticoidMice, Inbred C57BLMineralocorticoid Receptor AntagonistsDisease Models, AnimalMyocardial InfarctionTranscription Factor RelASulfonesAnimalsMaleMiceRAW 264.7 CellsSignal TransductionFibrosisTranscription, GeneticMyocardiumAnti-Inflammatory AgentsInterleukin-6Pyrroles

Stichwörter der Autor:innen

esaxerenoneinterleukin‐6mineralocorticoid receptormyocardial infarction

Substanzen

STAT3 Transcription FactorReceptors, MineralocorticoidMineralocorticoid Receptor AntagonistsStat3 protein, mouseTranscription Factor RelASulfonesesaxerenoneRela protein, mouseAnti-Inflammatory AgentsInterleukin-6

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine Graduate School of Medical Sciences, Kumamoto University Kumamoto Japan.
  • Department of General Medicine and Primary Care Kumamoto University Hospital Kumamoto Japan.
  • Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine University of Miyazaki Miyazaki Japan.
  • Division of Cardiology Arao City Hospital Arao Japan.
  • International Research Center for Medical Sciences Kumamoto University Kumamoto City Kumamoto Japan.
  • Center for Metabolic Regulation of Healthy Aging, Faculty of Life Sciences Kumamoto University Kumamoto Japan.

ORCID-Profile: Naoto Kuyama, Satoshi Araki, Koichi Kaikita, Naoya Nakashima, Shinsuke Hanatani, Yuichiro Arima, Masahiro Yamamoto, Taishi Nakamura, Kenichi Matsushita, Kunihiko Matsui, Kenichi Tsujita

Zitieren

APA

Kuyama, N., Araki, S., Kaikita, K., Nakanishi, N., Nakashima, N., Hanatani, S., Arima, Y., Yamamoto, M., Nakamura, T., Yamamoto, E., Matsushita, K., Matsui, K., & Tsujita, K. (2024). Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex. Journal of the American Heart Association, 13(18). https://doi.org/10.1161/jaha.123.030941

Vancouver

Kuyama N, Araki S, Kaikita K, Nakanishi N, Nakashima N, Hanatani S, et al. Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex. Journal of the American Heart Association. 2024;13(18). doi:10.1161/jaha.123.030941

BibTeX
@article{Kuyama2024,
  author = {Kuyama, Naoto and Araki, Satoshi and Kaikita, Koichi and Nakanishi, Nobuhiro and Nakashima, Naoya and Hanatani, Shinsuke and Arima, Yuichiro and Yamamoto, Masahiro and Nakamura, Taishi and Yamamoto, Eiichiro and Matsushita, Kenichi and Matsui, Kunihiko and Tsujita, Kenichi},
  title = {Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex},
  journal = {Journal of the American Heart Association},
  year = {2024},
  volume = {13},
  number = {18},
  doi = {10.1161/jaha.123.030941}
}
Kostenlos starten →